Drug Profile
Amlodipine/olmesartan - Hanlim Pharm
Alternative Names: LodivikarLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Hanlim Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Nicotinic acids; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (PO, Tablet)
- 01 Apr 2014 Phase-I clinical trials in Hypertension (In volunteers) in South Korea (PO) (NCT02955498)